The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Cutting Edge: Antimalarial Drugs Inhibit IFN-β Production through Blockade of Cyclic GMP-AMP Synthase–DNA Interaction
Abstract
Type I IFN is strongly implicated in the pathogenesis of systemic autoimmune diseases, such as lupus, and rare monogenic IFNopathies, including Aicardi–Goutières syndrome. Recently, a new DNA-activated pathway involving the enzyme cyclic GMP-AMP synthase (cGAS) was described and potentially linked to Aicardi–Goutières syndrome. To identify drugs that could potentially inhibit cGAS activity, we performed in silico screening of drug libraries. By computational analysis, we identified several antimalarial drugs (AMDs) that were predicted to interact with the cGAS/dsDNA complex. Our studies validated that several AMDs were effective inhibitors of IFN-β production and that they functioned by inhibiting dsDNA stimulation of cGAS. Because AMDs have been widely used in human diseases and have an excellent safety profile, our findings suggest new therapeutic strategies for the treatment of severe debilitating diseases associated with type I IFNs due to cGAS activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trott, O., & Olson, A. J. (2010) · Journal of Computational Chemistry · doi:10.1002/jcc.21334 · Cited by 38,412
Trex1 prevents cell-intrinsic initiation of autoimmunity
Stetson, D. B., Ko, J. S., Heidmann, T., & Medzhitov, R. (2008) · Cell · doi:10.1016/j.cell.2008.06.032 · Cited by 1,280
Diner, E. J., Burdette, D. L., Wilson, S. C., Monroe, K. M., Kellenberger, C. A., Hyodo, M., Hayakawa, Y., Hammond, M. C., & Vance, R. E. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.05.009 · Cited by 767
Lee-Kirsch, M. A., Gong, M., Chowdhury, D., Senenko, L., Engel, K., Lee, Y.-A., de Silva, U., Bailey, S. L., Witte, T., Vyse, T. J., et al. (2007) · Nature Genetics · doi:10.1038/ng2091 · Cited by 730
Cited by
The cGAS–STING pathway as a therapeutic target in inflammatory diseases
Decout, A., Katz, J. D., Venkatraman, S., & Ablasser, A. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00524-z · Cited by 2,309
Mechanisms of action of hydroxychloroquine and chloroquine:implications for rheumatology
Schrezenmeier, E., & Dörner, T. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0372-x · Cited by 1,468
The cGAS–cGAMP–STING pathway connects DNA damage to inflammation, senescence, and cancer
Li, T., & Chen, Z. J. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20180139 · Cited by 1,293
“So far the reported molecules are active against cGAS in vitro, but haven’t demonstrated desirable potency in vivo (An et al., 2015; Hall et al., 2017; Vincent et al., 2017).”
BackgroundSystemic lupus erythematosus: Diagnosis and clinical management
Fava, A., & Petri, M. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.11.001 · Cited by 754
Management strategies and future directions for systemic lupus erythematosus in adults
Durcan, L., O'Dwyer, T., & Petri, M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30237-5 · Cited by 648
Zhou, D., Dai, S.-M., & Tong, Q. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa114 · Cited by 600
Rodero, M. P., & Crow, Y. J. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20161596 · Cited by 433
Acetylation Blocks cGAS Activity and Inhibits Self-DNA-Induced Autoimmunity
Dai, J., Huang, Y.-J., He, X., Zhao, M., Wang, X., Liu, Z.-S., Xue, W., Cai, H., Zhan, X.-Y., Huang, S.-Y., et al. (2019) · Cell · doi:10.1016/j.cell.2019.01.016 · Cited by 371
Vincent, J., Adura, C., Gao, P., Luz, A., Lama, L., Asano, Y., Okamoto, R., Imaeda, T., Aida, J., Rothamel, K., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00833-9 · Cited by 370
Oduro, P. K., Zheng, X., Wei, J., Yang, Y., Wang, Y., Zhang, H., Liu, E., Gao, X., Du, M., & Wang, Q. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.05.011 · Cited by 339
Gonugunta, V. K., Sakai, T., Pokatayev, V., Yang, K., Wu, J., Dobbs, N., & Yan, N. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.061 · Cited by 323
Signaling by cGAS–STING in Neurodegeneration, Neuroinflammation, and Aging
Paul, B. D., Snyder, S. H., & Bohr, V. A. (2021) · Trends in Neurosciences · doi:10.1016/j.tins.2020.10.008 · Cited by 314
Small molecules targeting the innate immune cGAS‒STING‒TBK1 signaling pathway
Ding, C., Song, Z., Shen, A., Chen, T., & Zhang, A. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.03.001 · Cited by 306
Lama, L., Adura, C., Xie, W., Tomita, D., Kamei, T., Kuryavyi, V., Gogakos, T., Steinberg, J. I., Miller, M., Ramos-Espiritu, L., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08620-4 · Cited by 303
Type I Interferons in Autoimmune Disease
Crow, M. K., Olferiev, M., & Kirou, K. A. (2019) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043952 · Cited by 291
Cytosolic DNA sensing by cGAS: regulation, function, and human diseases
Yu, L., & Liu, P. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00554-y · Cited by 269
The Cyclopeptide Astin C Specifically Inhibits the Innate Immune CDN Sensor STING
Li, S., Hong, Z., Wang, Z., Li, F., Mei, J., Huang, L., Lou, X., Zhao, S., Song, L., Chen, W., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.097 · Cited by 267
Hu, X., Zhang, H., Zhang, Q., Yao, X., Ni, W., & Zhou, K. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02602-y · Cited by 258
Overcoming innate immune barriers that impede AAV gene therapy vectors
Muhuri, M., Maeda, Y., Ma, H., Ram, S., Fitzgerald, K. A., Tai, P. W. L., & Gao, G. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143780 · Cited by 212
The World Goes Bats: Living Longer and Tolerating Viruses
Gorbunova, V., Seluanov, A., & Kennedy, B. K. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.06.013 · Cited by 162
Steinhagen, F., Zillinger, T., Peukert, K., Fox, M., Thudium, M., Barchet, W., Putensen, C., Klinman, D., Latz, E., & Bode, C. (2018) · European Journal of Immunology · doi:10.1002/eji.201747338 · Cited by 112
Cytoplasmic Mechanisms of Recognition and Defense of Microbial Nucleic Acids
Hu, M.-M., & Shu, H.-B. (2018) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100617-062903 · Cited by 110
Immunomodulators in SLE: Clinical evidence and immunologic actions
Durcan, L., & Petri, M. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.06.010 · Cited by 92
“In turn the reduced toll-like receptor signaling results in decreased activation of dendritic cell and the reduction of interferon production [113], amongst other mechanisms [100].”
BackgroundCGAS is a micronucleophagy receptor for the clearance of micronuclei
Zhao, M., Wang, F., Wu, J., Cheng, Y., Cao, Y., Wu, X., Ma, M., Tang, F., Liu, Z., Liu, H., et al. (2021) · Autophagy · doi:10.1080/15548627.2021.1899440 · Cited by 89
Bode, C., Fox, M., Tewary, P., Steinhagen, A., Ellerkmann, R. K., Klinman, D., Baumgarten, G., Hornung, V., & Steinhagen, F. (2016) · European Journal of Immunology · doi:10.1002/eji.201546113 · Cited by 79
Chandler, L. C., Barnard, A. R., Caddy, S. L., Patrício, M. I., McClements, M. E., Fu, H., Rada, C., MacLaren, R. E., & Xue, K. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.05.012 · Cited by 50
Chandler, L., Yusuf, I., McClements, M., Barnard, A., MacLaren, R., & Xue, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144972 · Cited by 49
miR-23a/b suppress cGAS-mediated innate and autoimmunity
Yu, Q., Chu, L., Li, Y., Wang, Q., Zhu, J., Wang, C., & Cui, S. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00668-x · Cited by 37
Metadata
- Authors
- An, J., Woodward, J. J., Sasaki, T., Minie, M., & Elkon, K. B.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-05-01
- Volume
- 194
- Issue
- 9
- Pages
- 4089-4093
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1594574415
- Cited by
- 239
- References
- 4
- FWCI
- 4.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.